Sigma Healthcare (ASX:SIG) is a pharmacy franchisor, wholesaler and distributor operating across the Chemist Warehouse network, Amcal and discount drugstore banners, and pharmaceutical distribution. Following the Merger with Chemist Warehouse, the group now spans close to 1,000 pharmacies across Australia and international markets. Its FY26 result showed strong Revenue and Earnings growth, while the main areas to watch in FY27 are integration progress, working capital, synergy delivery and the pace of international expansion.

FY26 Revenue and Earnings Increase

For FY26, Sigma reported sales revenue of $10.8 billion, reflecting the first full year of the combined Sigma and Chemist Warehouse group. Net profit after tax attributable to owners was $709.2 million, while Earnings Per Share were 6.2 cents. Normalised EBIT reached $1,090.0 million, representing growth of 20.6 per cent.

The result showed a substantial increase in the scale of the Business following the merger. The enlarged group now combines pharmacy retail, franchising, wholesale distribution and international operations, giving it exposure to multiple revenue streams across the healthcare and consumer pharmacy market.

Chemist Warehouse Network Sales Remain the Main Growth Driver

Chemist Warehouse branded network sales reached $10.2 billion during FY26, with Australian like-for-like sales growth of 13.4 per cent. This indicates that growth was not driven solely by new store additions, but also by higher sales from the existing store base.

The network added 24 stores in Australia during the year, which further expanded the domestic footprint. The combination of like-for-like growth and store openings remains central to the group's earnings outlook, particularly as management has indicated that double-digit like-for-like growth resumed in the new financial year.

International Expansion Accelerates

International revenue increased 33 per cent to $421.4 million, supported by store growth across overseas markets. The group added 20 international stores during FY26, while Ireland reached profitability for the first time and New Zealand store sales increased by around 20 per cent.

Expansion into the United Kingdom is also progressing, with two stores planned before Christmas and a further three expected to follow. Management has indicated that the UK business is likely to remain loss-making during its early scaling phase, meaning the rollout is expected to add cost before it becomes a meaningful earnings contributor.

New Reporting Structure Highlights Geographic Growth

Sigma introduced two reporting segments, Australia and International, replacing the previous single-segment structure. The change reflects the increasing importance of overseas operations within the combined group and provides greater visibility into where growth is being generated.

The Australian business remains the primary earnings base, but international expansion is becoming a more material part of the group's strategy. As that contribution grows, investors will be able to assess more clearly whether overseas markets can deliver returns comparable with the established Australian network.

Synergy Delivery Remains an Important Integration Measure

The combined group delivered $32.6 million of synergies during FY26 against a target of $100 million annually by FY29. These savings are expected to come from integration across procurement, distribution, systems and other operating areas.

The current level indicates that the integration programme is still in its early stages. Further progress will be important because the financial case for the merger depends partly on extracting efficiencies from the enlarged network while maintaining service levels and store growth.

For Sigma Healthcare (ASX:SIG), the pace at which synergies rise toward the FY29 target will therefore be one of the main measures of execution.

Cash Conversion Remains Solid but Working Capital Expands

Operating cash flow was $574.6 million, representing cash conversion of 81.1 per cent. While this indicates that a substantial portion of earnings translated into cash, the cash conversion cycle lengthened to 54 days from 46.9 days.

Inventory increased by 22 per cent, reflecting growth in own-label products and changes in supplier arrangements. Higher inventory can support network expansion and product availability, but it also ties up more working capital and can reduce free cash generation if the increase is not matched by sales growth.

The longer cash conversion cycle therefore deserves attention in FY27, particularly as international expansion and new distribution infrastructure add further demands on working capital.

Margin Mix Is Affected by GLP-1 Medicines

Gross Margin declined to 18.1 per cent, partly because of higher sales of lower-margin GLP-1 medicines. These products contributed to revenue growth but diluted the overall margin mix.

This illustrates how product composition can affect profitability even when sales are rising. If lower-margin categories continue to grow faster than higher-margin products, revenue growth may not translate proportionately into profit.

The group will therefore need to balance Volume growth with category mix, supplier Economics and operating efficiency.

Net Debt Declines

Net debt fell to $663.2 million from $752.2 million, equivalent to 0.57 times normalised EBITDA. The decline indicates that the group maintained a relatively moderate Leverage position despite ongoing integration and expansion.

Lower leverage provides greater financial flexibility for store openings, distribution Investment and international growth. It also gives the company more capacity to absorb temporary earnings pressure from new markets such as the United Kingdom.

Balance-sheet discipline will remain important as Capital Expenditure increases across logistics and automation projects.

Dividend Remains Within the Payout Framework

Sigma declared interim and final dividends of 2.0 cents per share each, taking the full-year total to 4.0 cents per share. The final Dividend was fully franked and was paid on 22 September 2026.

The full-year dividend remained within the company's stated payout range of 50 to 70 per cent of profit. This indicates that the group is returning capital to shareholders while retaining a meaningful portion of earnings to fund integration, working capital and growth.

Future dividend capacity will depend on earnings growth, cash conversion and the capital requirements associated with international expansion.

Amcal and Discount Drugstore Membership Needs Monitoring

Amcal and discount drugstore membership declined during the merger transition, although management reported that 82 new members had committed for FY27. This suggests some stabilisation, but the pace at which those new commitments convert into active stores will be important.

Membership trends matter because these banners form part of Sigma's broader Franchise and wholesale network. A sustained decline could weaken scale benefits, while successful onboarding of new members would support distribution volumes and franchise economics.

New Zealand Distribution Investment Adds Execution Risk

The group plans a new distribution centre in New Zealand with a budget of $40 million and an 18-month automation timeline. The project is intended to support growth and improve supply-chain efficiency, but it also introduces construction and implementation risk.

Automation projects can improve productivity once fully operational, but delays, integration issues or cost overruns can reduce the expected benefits. The timing of the New Zealand project will therefore be relevant as the international network continues to expand.

FY27 Growth Depends on Consistent Execution

Management has indicated that Australian double-digit like-for-like sales growth resumed in the new financial year. Maintaining that momentum will be important, particularly because FY26 included some weaker sales in May and June, which management linked to strong prior-year comparisons and a delayed cold and flu season.

The uneven monthly pattern shows that growth can fluctuate even within a broader positive trend. FY27 performance will therefore depend on maintaining store traffic, category growth and network expansion while also managing working capital and integration costs.

Key Risks and Uncertainties

Working capital is one of the main financial risks because inventory has increased and the cash conversion cycle has lengthened. If inventory continues to rise faster than sales, more cash could remain tied up in the business.

International expansion also carries execution risk, particularly in the United Kingdom where early losses are expected. Cybersecurity, merger integration and cost-of-living pressures provide additional uncertainty, while lower-margin product categories could continue to affect gross margin.

The group also needs to deliver its synergy programme while maintaining operational reliability across a much larger network.

What to Watch in FY27

The planned 13 Australian store openings in the first half of FY27 will provide an early measure of network expansion, while the launch of the first UK stores before Christmas will show how the international rollout is progressing.

The New Zealand distribution centre and automation project will also be important, alongside further synergy delivery toward the $100 million annual FY29 target. Investors can monitor whether the cash conversion cycle improves and whether inventory growth begins to normalise.

The FY27 half-year result should provide the clearest indication of whether strong Australian like-for-like sales, international expansion and integration benefits are translating into sustained earnings growth. For Sigma Healthcare (ASX:SIG), FY26 showed that the merged group has substantial scale and growth momentum, but FY27 will test how effectively that growth can be converted into cash and margin improvement.